

## Alzinova presents at Redeye Investor AW - Gothenburg

Alzinova AB (publ) ("Alzinova" or the "Company") will present today, December 15, at Redeye Investor AW in Gothenburg, the presentation is held at 19.05. Alzinovas CEO Kristina Torfgård will present the Company's business and provide an update on the ongoing Phase 1b study of the vaccine candidate ALZ-101 against Alzheimer's disease.

CEO Kristina Torfgård will present Alzinova and provide an update on the Company's vaccine candidate for Alzheimer's disease, ALZ-101, and the ongoing Phase 1b study at the live Redeye Investor AW event in Gothenburg on December 15 at 7:05 p.m. The live broadcast of the event can be viewed on Redeye's website at: https://www.redeye.se/events/850217/investor-awgoteborg-5

## For more information, please contact:

Kristina Torfgård, CEO Tel. +46 708 46 79 75

E-mail: kristina.torfqard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

## **About Alzinova**

Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary AβCC peptide<sup>™</sup> technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

## **Attachments**

Alzinova presents at Redeye Investor AW - Gothenburg